作为阿尔茨海默病候选药物的西尔德纳菲尔:真实世界患者数据观察和来自患者诱导的多能干细胞衍生神经元的机械观察

Dhruv Gohel1, Pengyue Zhang2, Amit Kumar Gupta1

  • 1Genomic Medicine Institute,Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

概括

西尔德纳菲尔在降低阿尔茨海默病 (AD) 风险和病理学方面表现有前途. 现实世界的数据和来自患者的神经元表明,西尔德纳菲尔是阿尔茨海默病的潜在治疗药物,尽管需要进行临床试验.

相关概念视频

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188